What is the global market size of Vaccine Adjuvants Market?

Global Vaccine Adjuvants Market size was valued at USD 0.9 billion in 2021 and is poised to grow from USD 1.31 billion in 2022 to USD 2.90 billion by 2030, growing at a CAGR of 11.9% during the forecast period (2023-2030).

Who are the key vendors in the Global Vaccine Adjuvants Market?

The global vaccine adjuvants market is characterized by a diverse range of companies striving to innovate and meet the growing demand for adjuvant products. Market players are engaged in extensive research and development activities to enhance the effectiveness and safety of adjuvants. Additionally, partnerships, collaborations, and acquisitions are common strategies adopted by companies to strengthen their market position. The competitive environment fosters a continuous drive for technological advancements, improved manufacturing processes, and the development of novel adjuvant formulations, contributing to the overall growth and competitiveness of the market. 'CSL Limited (Australia)', 'GlaxoSmithKline plc (United Kingdom)', 'Novavax, Inc. (US)', 'SEPPIC (France)', 'Agenus Inc. (US)', 'InvivoGen (US)', 'Brenntag Biosector (Denmark)', 'Avanti Polar Lipids, Inc. (US)', 'Vaxine Pty Ltd. (Australia)', 'SPI Pharma (US)', 'OZ Biosciences (France)', 'CureVac AG (Germany)', 'Adjuvatis (France)', 'Advanced BioAdjuvants Corporation (US)', 'Adjuvance Technologies Inc. (US)', 'SDA Bio (Italy)', 'Bio Products Laboratory Ltd. (United Kingdom)', 'GSK Vaccines GmbH (Germany)', 'Mucosis B.V. (Netherlands)', 'NanoBio Corporation (US)'.

What is the key driver of Global Vaccine Adjuvants Market?

One key driver for the growth of the global vaccine adjuvants market is the increasing focus on the development of innovative vaccines against emerging and existing diseases. As new infectious diseases continue to emerge and existing ones evolve, there is a growing need for vaccines with enhanced immunogenicity and long-lasting efficacy. Adjuvants play a crucial role in boosting the immune response and improving vaccine effectiveness. The demand for vaccine adjuvants is driven by the imperative to develop advanced vaccines that can effectively combat these evolving and challenging diseases.

What is the key market trend for Global Vaccine Adjuvants Market?

The rising need for innovative adjuvant formulations is a significant trend in the world market for vaccine adjuvants. As there is a greater need for effective vaccines, researchers are creating and implementing cutting-edge adjuvant technologies to improve vaccine efficacy and durability. The use of cutting-edge adjuvant substances and delivery technologies that promote potent immune responses while minimising negative effects is included in this.

Which region accounted for the largest share in Global Vaccine Adjuvants Market?

North America dominated the global vaccine adjuvants market. The United States is a developed country with a substantial population, resulting in a high demand for immunization and vaccine-related products. Additionally, the country experiences a large influx of travelers, which further emphasizes the importance of immunization to ensure public health and safety. Furthermore, the United States has a well-established healthcare infrastructure and favorable government initiatives that support immunization programs, thereby driving the demand for vaccine adjuvants.

Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2155 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 60 | Figures: 75

Vaccine Adjuvants Market News

May 2023: US companies Amyris and Botanical Solutions Inc (BSI) partnered with UK specialty chemicals company Croda through collaboration agreements to produce renewable vaccination adjuvants.
January 2023: Elicio Therapeutics is developing multiple immunotherapies based on its proprietary lymph node-targeting Amphiphile technology, AMP to develop ELI-002, a therapeutic cancer vaccine designed to target mKRAS-driven tumors. The firm reached a definitive merger agreement with Angion Biomedica Corp. The firm there focuses on the engineering of lymph node-targeted adjuvants and vaccines for different aggressive cancers and infectious diseases.
March 2022: Croda received an exclusive license to market adjuvants for the SSI CAF vaccine. The vaccine adjuvants business is anticipated to expand with the impression that SSI cationic adjuvants have massive prospects for future vaccine development.

Vaccine Adjuvants Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% in the forecast period (2024-2031).

Business diversity in developing and meeting the emergent demand for adjuvant products characterizes the global vaccine adjuvants market. Market players are investing considerable funds in R&D with a focus on increasing the safety and efficacy of adjuvants. In addition, firms often adopt partnerships, collaborations, and acquisitions as steps to boost their market position. The competitive environment increased the market competitiveness, and it has also grown overall because it encourages an ongoing attempt to upgrade the production techniques, create new adjuvant formulas, and new technology. 'CSL Limited (Australia)', 'GlaxoSmithKline plc (United Kingdom)', 'Novavax, Inc. (US)', 'SEPPIC (France)', 'Agenus Inc. (US)', 'InvivoGen (US)', 'Brenntag Biosector (Denmark)', 'Avanti Polar Lipids, Inc. (US)', 'Vaxine Pty Ltd. (Australia)', 'SPI Pharma (US)', 'OZ Biosciences (France)', 'CureVac AG (Germany)', 'Adjuvatis (France)', 'Advanced BioAdjuvants Corporation (US)', 'Adjuvance Technologies Inc. (US)', 'SDA Bio (Italy)', 'Bio Products Laboratory Ltd. (United Kingdom)', 'GSK Vaccines GmbH (Germany)', 'Mucosis B.V. (Netherlands)', 'NanoBio Corporation (US)'

The increased global health concerns brought by the COVID-19 pandemic and up need for higher levels of vaccinations, especially adjuvant-based. This is attributed to the requirements for an effective vaccination approach toward various infectious diseases and new emerging pathogens in preserving community immunity. Accordingly, the vaccine manufacturing continues to find ways to enhance vaccination potency by investing in the latest technology in adjuvant.

Personalized Immunization Plans: One of the major and latest approaches observed in the vaccine adjuvants market is the shift toward customized vaccination strategies. Researchers have started to prepare specific vaccines depending on the uniqueness of every patient, such as genetic and immune system-specific differences. To phrase it simply, this approach seeks to further enhance the effectiveness of vaccinations, hence the outcomes of patients, by enabling a more efficient immunization strategy, which would involve specific adjuvants designed for various patients to deliver the most efficacious responses.

Due to the well-established healthcare system and significant investments in R&D, North America accounted for the highest share in the vaccine adjuvants market revenue in 2023. The region houses large industrial companies that feature a wide array of vaccine adjuvants, which are used in commercial as well as research-oriented fields. It has leading biotech and pharmaceutical firms, which foster innovation and make it relatively easier to produce compositions that work as adjuvants. In addition, continued technical advances in adjuvant mechanisms and vaccine delivery modalities for various disease applications are fueling growth in North America and ensuring strong public health plans and responses to emerging health risks.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route), By Region - Industry Forecast 2024-2031

Vaccine Adjuvants Market News

Vaccine Adjuvants Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Vaccine Adjuvants Market?

Who are the key vendors in the Vaccine Adjuvants Market?

What is the key driver of Vaccine Adjuvants Market?

What is the key market trend for Vaccine Adjuvants Market?

Which region accounted for the largest share in Vaccine Adjuvants Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300